/C O R R E C T I O N -- Ranok Therapeutics/
PR Newswire
WALTHAM, Mass. and HANGZHOU, China, June 1, 2026
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026, issued 01-Jun-2026 by Ranok Therapeutics over PR Newswire, we are advised by the company that the first sub-headline, the 3rd paragraph, and the contact details have been updated. The complete, corrected release follows:
Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
